Lack of immunomodulating effect of disulfiram on HIV positive patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Lack of immunomodulating effect of disulfiram on HIV positive patients. / Hørding, M; Gøtzsche, P C; Bygbjerg, Ib Christian; Christensen, L D; Faber, V.
In: International Journal of Immunopharmacology, Vol. 12, No. 2, 01.01.1990, p. 145-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Lack of immunomodulating effect of disulfiram on HIV positive patients
AU - Hørding, M
AU - Gøtzsche, P C
AU - Bygbjerg, Ib Christian
AU - Christensen, L D
AU - Faber, V
PY - 1990/1/1
Y1 - 1990/1/1
N2 - Disulfiram (Antabuse (R)) is metabolized to two molecules of diethyldithiocarbamate, which has been reported to be an immunomodulating agent. In a double blind trial, 15 HIV antibody positive homosexual men were given daily doses of 100 mg or 400 mg of disulfiram or placebo, for 4 weeks. All had a CD4-count below 500 X 10(6)/l and/or a pokeweed mitogen response in a lymphocyte proliferation assay less than 50% of normal controls. None suffered from opportunistic infections. No significant effect of disulfiram on immunological, haematological, biochemical or clinical variables was observed in this short-term trial.
AB - Disulfiram (Antabuse (R)) is metabolized to two molecules of diethyldithiocarbamate, which has been reported to be an immunomodulating agent. In a double blind trial, 15 HIV antibody positive homosexual men were given daily doses of 100 mg or 400 mg of disulfiram or placebo, for 4 weeks. All had a CD4-count below 500 X 10(6)/l and/or a pokeweed mitogen response in a lymphocyte proliferation assay less than 50% of normal controls. None suffered from opportunistic infections. No significant effect of disulfiram on immunological, haematological, biochemical or clinical variables was observed in this short-term trial.
KW - Adjuvants, Immunologic
KW - Disulfiram
KW - HIV Seropositivity
KW - Humans
KW - Male
KW - Randomized Controlled Trials as Topic
KW - Time Factors
M3 - Journal article
C2 - 2184133
VL - 12
SP - 145
EP - 147
JO - International Journal of Immunopharmacology
JF - International Journal of Immunopharmacology
SN - 0192-0561
IS - 2
ER -
ID: 33891068